Physician profile
Ali Jaffry
NPI 1871119925
$5,604.09
in general payments reported to CMS, 2019-2025
10 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what 92% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $394 · 2022: $851 · 2023: $1,708 · 2024: $1,540 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,356 · Education: $3.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,355.90 |
| Education | $3.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $3,458.40 | 2022-2025 | Infuse, Miebo, Vyzulta |
| Alcon Vision LLC | $603.59 | 2022-2025 | Total30, Precision 1, Dailies Total1 |
| Johnson & Johnson Vision Care, INC. | $467.38 | 2021-2025 | Acuvue |
| Coopervision INC. | $463.63 | 2022-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $367.33 | 2021 | |
| Sun Pharmaceutical Industries INC. | $89.56 | 2023-2025 | Cequa |
| Lkc Technologies, INC. | $83.33 | 2023 | |
| Abbvie INC. | $32.26 | 2024 | |
| Novartis Pharmaceuticals Corporation | $21.04 | 2022 | |
| Kala Pharmaceuticals, INC. | $17.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Jaffry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.